Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GenVec has signed an R&D agreement with the National Institute of Allergy and Infectious Diseases to develop adenovector-based vaccines for the prevention and treatment of respiratory syncytial virus.
Subscribe to our email newsletter
In addition to the RSV collaboration, the biopharmaceutical firm is working with the institute on the clinical development of HIV and influenza vaccines.
“Data emerging from the clinical trials of our HIV vaccine candidate indicates that GenVec’s adenovector technology induces both antibodies and cellular immune responses,” said Rick King, GenVec’s senior vice president of research.